TNFRSF8 and mature T-cell and NK-cell non-Hodgkin lymphoma: Based on this encouraging phase 1 data, a global double-blind, randomized phase 3 study (ECHELON-2, NCT01777152) was initiated in 2013 comparing BV-CHP with standard CHOP in untreated CD30-positive PTCL (targeting 75% ALCL) [70], and randomized 452 patients.